A phase 2 trial of fludarabine / melphalan 100 conditioning therapy followed by allogeneic hematopoietic cell transplantation for patients with lymphoma

Conclusion Conditioning therapy with a lower dose of melphalan in combination with fludarabine appears to be promising in allogeneic HCT for lymphoma. This study was registered at www.Clinicaltrials.gov as #NCT00772811. Graphical abstract
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research